Form 4 for AVIR Atea Pharmaceuticals, Inc.
Accepted 2026-02-03 00:00:00 ET · period of report 2026-01-31 · accession 0001193125-26-036268 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-03 | 2026-01-31+ | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | M - OptEx | $1.24 | +573.0K | 573.9K | +60,956% | +$710.5K |
| D | 2026-02-03 | 2026-01-31 | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | F - Tax | $4.24 | -106.1K | 467.8K | -18% | -$449.8K |
| DM | 2026-02-03 | 2026-01-31+ | AVIR | Sommadossi Jean-Pierre | Pres, CEO, COB, Dir | M - OptEx | $0.00 | -573.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-03 | M | A | 300,000 | $1.24 | 767,830 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-31 | F | D | 106,093 | $4.24 | 467,830 | D | — | — | |
| 3 | Common | Common Stock | 2026-01-31 | M | A | 272,983 | — | 573,923 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-02-03 | M | D | 300,000 | $0.00 | 0 | D | $1.24 · — to 2026-12-08 | 300,000 Common Stock | (F5) The option is fully vested and exercisable. |
| 5 | Derivative | Restricted Stock Units | 2026-01-31 | M | D | 173,466 | $0.00 | 0 | D | — · — to — | 173,466 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F2) The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. |
| 6 | Derivative | Restricted Stock Units | 2026-01-31 | M | D | 99,517 | $0.00 | 0 | D | — · — to — | 99,517 Common Stock | (F4) Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026. (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F3) Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. |